There are 840 beds in Uniwersytecki Szpital Kliniczny w Bialymstoku.

During the past decade, Uniwersytecki Szpital Kliniczny w Bialymstoku conducted 37 clinical trials. In the 10-year time frame, 37 clinical trials started and 24 clinical trials were completed, i.e. on average, 64.9% percent of trials that started reached the finish line to date. In the past 5 years, 19 clinical trials started and 19 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Uniwersytecki Szpital Kliniczny w Bialymstoku" #1 sponsor was "Bayer" with 6 trials, followed by "Shire" with 5 trials sponsored, "Hoffmann-La Roche" with 3 trials sponsored, "United Therapeutics" with 3 trials sponsored and "BeiGene" with 3 trials sponsored. Other sponsors include 30 different institutions and companies that sponsored additional 36 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Uniwersytecki Szpital Kliniczny w Bialymstoku" #1 collaborator was "Merck Sharp & Dohme LLC" with 2 trials as a collaborator, "ABX CRO" with 1 trials as a collaborator, "AG Mednet Inc." with 1 trials as a collaborator, "ANRS, Emerging Infectious Diseases" with 1 trials as a collaborator and "Abbott" with 1 trials as a collaborator. Other collaborators include 27 different institutions and companies that were collaborators in the rest 37 trials.

According to Clinical.Site data, the most researched conditions in "Uniwersytecki Szpital Kliniczny w Bialymstoku" are "Ulcerative Colitis" (6 trials), "Pulmonary Arterial Hypertension" (5 trials), "Crohn's Disease" (3 trials), "Diffuse Cutaneous Systemic Sclerosis" (3 trials) and "Acute Myocardial Infarction" (2 trials). Many other conditions were trialed in "Uniwersytecki Szpital Kliniczny w Bialymstoku" in a lesser frequency.

Most popular intervention types in "Uniwersytecki Szpital Kliniczny w Bialymstoku" are "Drug" (46 trials), "Other" (8 trials), "Biological" (5 trials), "Device" (2 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (24 trials), "Ontamalimab" (4 trials), "Ocrelizumab" (3 trials), "Apixaban" (2 trials) and "Enoxaparin" (2 trials). Other intervention names were less common.

The vast majority of trials in "Uniwersytecki Szpital Kliniczny w Bialymstoku" are 52 trials for "All" genders, 1 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Uniwersytecki Szpital Kliniczny w Bialymstoku". undefined are not yet recruiting, 8 are recruiting, 6 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 29 completed trials in Uniwersytecki Szpital Kliniczny w Bialymstoku, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in Uniwersytecki Szpital Kliniczny w Bialymstoku, 1 "Phase 1" clinical trials were conducted, 17 "Phase 2" clinical trials and 31 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

Uniwersytecki Szpital Kliniczny w Bialymstoku has several departments that took part in Clinical trials: "Uniwersytecki Szpital Kliniczny w Bialymstoku, Klinika Gastroenterologii i Chorob Wewnetrznych" - 3 trials, "Uniwersytecki Szpital Kliniczny w Bialymstoku, Klinika Kardiologii z Oddzialem Intensywnego Nazdoru Kardiologicznego, M. Sklodowskiej 24a" - 2 trials